|Bid||43.28 x 800|
|Ask||43.38 x 800|
|Day's Range||42.53 - 44.65|
|52 Week Range||2.14 - 52.55|
|Beta (3Y Monthly)||-0.11|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 24, 2018 - Oct 29, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||50.45|
Tandem Diabetes Care®, Inc. , a leading insulin delivery and diabetes technology company, plans to release its fourth quarter and full year 2018 results after the financial markets close on Tuesday, February 26, 2019.
NEW YORK, NY / ACCESSWIRE / January 11, 2019 / U.S. markets finished in the green on Thursday, however gains were held back by a sharp decline in Macy’s shares that pressured retail stocks lower. The Dow ...
NEW YORK, NY / ACCESSWIRE / January 9, 2019 / U.S. equities closed up on Tuesday as market participants await details from the recent negotiations in Washington between U.S. and senior Chinese officials. ...
These healthcare stocks crushed the S&P 500's return last year, but that doesn't guarantee they'll be top performers in 2019.
Tandem Diabetes Care®, Inc. (TNDM), a leading insulin delivery and diabetes technology company, today announced that Rebecca (Beckie) Robertson was appointed as an independent member of its board of directors. “Beckie has an impressive track-record of helping medical device companies scale in her roles as an engineer, entrepreneur, corporate executive and board member,” said Kim Blickenstaff, president and CEO of Tandem Diabetes Care. “It’s an exciting time to welcome Beckie to our Board,” said Dick Allen, chairman of Tandem Diabetes Care.
Tandem Diabetes Care, Twilio, and Amarin each had powerhouse returns in 2018 -- but one was a real standout performer for its shareholders.
Tandem Diabetes Care (TNDM) stock grew from $2.36 on December 29, 2017, to reach $37.31 at the close of market on December 28, 2018, an increase of ~1,481% this year. Its price on December 28 was ~4.13% higher than its prior day close of $35.83. On December 26, the company’s stock price closed at $36.47, which is a ~13.58% rise from its prior day close of $32.11.
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is Read More...
“October lived up to its scary reputation—the S&P 500 falling in the month by the largest amount in the last 40 years, the only worse Octobers being ’08 and the Crash of ’87. For perspective, there have been only 5 occasions in those 40 years when the S&P 500 declined by greater than 20% from […]
NEW YORK, NY / ACCESSWIRE / December 12, 2018 / U.S. equities finished lower on Tuesday after bouncing between the red and green territory. The stocks gained more than 1% across the board on improving ...
Investors need to pay close attention to Tandem Diabetes (TNDM) stock based on the movements in the options market lately.
After a phenomenal run from $2.52 on January 5 to a high of $51.17 on September 13, Tandem Diabetes Care (TNDM) stock slid to $28.45 on November 20. Tandem Diabetes Care’s revenue rose an impressive 71.33% from $27.0 million in the third quarter of 2017 to $46.26 million in the third quarter of 2018. Tandem Diabetes incurred a net loss of $73.03 million in 2017.
NEW YORK, Dec. 03, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Tandem Diabetes (TNDM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
On November 21, Tandem Diabetes Care (TNDM) stock closed at $32.63, a ~14.69% rise from its previous day’s close of $28.45.
DexCom (DXCM) and Verily to collaborate on the development of additional products and software based on DexCom's profile in the future.
AQR Capital Management is a $226 billion global investment management firm launched back in 1998, by a guru in the financial world, billionaire Cliff Asness. Among other accomplishments, he became well regarded in the investing universe, thanks to his doctoral dissertation for which he closely studied the use of technical analysis to determine undervalued stocks. During […]
This month, of the total ten analysts covering Tandem Diabetes Care (TNDM), seven have given the stock a “buy” or higher rating and three have given it a “hold” rating. The mean rating for Tandem Diabetes Care stock is 2.1 with a price target of $52.8, implying an upside potential of 65% over the closing price of $32.0 on November 13.
For fiscal 2018 and 2019, Tandem Diabetes Care’s gross margins are expected at 47.13% and 51.78%, respectively, compared with 40% in fiscal 2017. The fiscal 2018 gross margins of peers DexCom (DXCM), Insulet (PODD), and Johnson & Johnson (JNJ) are expected at 64.29%, 65.59%, and 70.43%, respectively. Tandem Diabetes Care incurred selling, general, and administrative expenses of $29.51 million in the third quarter of 2018, versus $20.12 million in the third quarter of 2017.
Tandem Diabetes Care’s (TNDM) interest and other expenses fell from $2.93 million in the third quarter of 2017 to $1.40 million in the latest quarter. Tandem Diabetes Care’s net loss widened from $16.03 million in the third quarter of 2017 to $34.26 million in the latest quarter, which translated into a net loss per share of $0.62 in the third quarter of 2018. Its net loss per share was $3.09 in the third quarter of 2017. Tandem Diabetes Care stock rose significantly from $2.52 on January 5 to $51.17 on September 13, which was its high point for 2018.